ideasIdea
BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer
Add immunotherapy to the two targeted pills in the most aggressive thyroid cancer, because the combination has produced multi-year survivors in early series.
ATC has high PD-L1 expression and TMB; MD Anderson reports of dabrafenib-trametinib-pembrolizumab show median OS beyond 2 years in BRAF-mutant patients versus ~15 months with the doublet.
Hypothesis
Adding pembrolizumab to dabrafenib-trametinib extends OS in BRAF V600E ATC.
Rationale
Targeted therapy induces rapid immunogenic response and antigen release; ATC is immunologically hot relative to differentiated cancers.
What would test it
International randomised phase 2 (doublet vs triplet) given rarity, with OS at 12 months as primary endpoint.
Maturity
early clinical
Pages like this
not linked directly; found by shared links- PairingBRAF/MEK inhibition → surgery in anaplastic thyroid cancer
Shares ROAR (anaplastic thyroid cancer cohort), Dabrafenib + trametinib, BRAF, Thyroid cancer.
- TrialCOMBI-AD
Shares Dabrafenib + trametinib, BRAF.
- TrialDREAMseq (ECOG-ACRIN EA6134)
Shares Dabrafenib + trametinib, BRAF, PD-1.
- PersonAntoni Ribas
Shares BRAF, PD-1, Pembrolizumab.
- PairingBRAF inhibitor + MEK inhibitor
Shares Dabrafenib + trametinib, BRAF.
- PersonKeith T. Flaherty
Shares Dabrafenib + trametinib, BRAF.
- TrialDECISION
Shares BRAF, Thyroid cancer.
- CollectionMelanoma Research Alliance (MRA)